BioSpace News Archive

Drug Development

Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced an oral presentation will be given at the 28th EADV Congress.

July 31, 2019
·
5 min read
Biotech Beach

Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference

Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET.

July 31, 2019
·
1 min read
Business

VMS BioMarketing Announces Appointment of Brion Brandes as SVP of Business Development

Attracting Top Talent Will Enable VMS to Continue Expanding Its Clinical Nurse Educator Programs to Help More Patients Served by the Biopharma Industry

July 31, 2019
·
2 min read
Deals

Esperion to Report Second Quarter 2019 Financial Results August 8, 2019

Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.

July 31, 2019
·
5 min read
Business

Charles River Labs to Launch Bay Area CRADL Facility in 2020

Charles River Labs will open its CRADL facility in South San Francisco in January 2020 in order to provide flexible, turnkey vivarium rental space for startups.

July 31, 2019
·
4 min read
·
Mark Terry and Alex Keown
Policy

HHS Announces Possible Roadmap for Importing Drugs from Canada

As reported yesterday, the Trump administration is evaluating proposals to allow consumers to buy drugs legally from Canada. Today, their efforts became more official as the U.S. Department of Health and Human Services announced their intentions.

July 31, 2019
·
4 min read
·
Mark Terry
Deals

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases

July 31, 2019
·
8 min read
Drug Development

Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering

Daiichi Sankyo Europe GmbH announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study (also known as Study 053) were published in the European Journal of Preventative Cardiology.

July 31, 2019
·
6 min read
Deals

Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019

Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.

July 31, 2019
·
2 min read
European CNS specialist Neuraxpharm launches first products in the United Kingdom

Craig Bowen appointed as General Manager of Neuraxpharm UK

July 31, 2019
·
3 min read